Dynavax Technologies Corporation
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Dynavax Technologies Corporation sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).
Dynavax Technologies Corporation: 16 sponsored US clinical trials, 1 recruiting.
Dynavax Technologies Corporation sponsors 16 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 11 completed. 3 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis, with 1 trials.
Top-decile sponsor footprint
Dynavax Technologies Corporation ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (73.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
16 total, page 1 of 1
Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
NCT07207408
Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age
NCT05506969
HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis
NCT03934736
Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC
NCT03326752
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT02521870
Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
NCT02266147
Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine
NCT02117934
A Study of the Immune Response to Heplisav in Healthy Older Adults
NCT01999699
Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease
NCT01282762
Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine
NCT01005407
Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients
NCT00985426
Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males
NCT00599001
Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine
NCT00511095
A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer
NCT00403052
Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults
NCT00387738
Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients
NCT00426712
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 4 |
| Phase 3 | 3 |
What is open in the Dynavax Technologies Corporation pipeline
1 recruiting of 16 indexed (6% open); 11 completed (69%).
Phase mix: 3 late (III/IV) vs 12 early (I/II) (early-phase heavy).
Top condition: Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Dynavax Technologies Corporation: open-pipeline peers nationwide
Peers matched on 16 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
Dynavax Technologies Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 16 trials (± recruiting share)
- Accelerated Community Oncology Research Network · 16 trials · 0% recruiting
- Altimmune · 16 trials · 6% recruiting
- American University · 16 trials · 13% recruiting
- Anthera Pharmaceuticals · 16 trials · 0% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Albert Einstein Healthcare Network · 6% recruiting · 48 trials
- Bassett Healthcare · 6% recruiting · 16 trials
- East Tennessee State University · 6% recruiting · 16 trials
- Monell Chemical Senses Center · 6% recruiting · 16 trials
Related
What to do with this Dynavax Technologies Corporation page
16 registered trials is a research-attention snapshot, not an endorsement of Dynavax Technologies Corporation or any single study.
- 1 of Dynavax Technologies Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis is the condition Dynavax Technologies Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Dynavax Technologies Corporation pipeline card: 16 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.